Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JNJ-73763989 + JNJ-64300535 + nucleos(t)ide analogs + JNJ-64301736
- Development stage
- Discontinued
- Lead developer
- OMJ Pharmaceuticals
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Administration
- Oral, Subcutaneous, Intramuscular
01
Overview
JNJ-73763989 + JNJ-64300535 + nucleos(t)ide analogs + JNJ-64301736 is a multi-modal combination therapy regimen developed by Janssen for the treatment of chronic hepatitis B virus (HBV) infection. The regimen is designed to achieve a functional cure by targeting multiple stages of the HBV lifecycle and stimulating the host immune response. It consists of JNJ-73763989, an RNA interference (RNAi) therapeutic that silences all HBV RNA transcripts; JNJ-64300535, a capsid assembly modulator (CAM) that interferes with viral nucleocapsid formation; standard-of-care nucleos(t)ide analogs (NAs) that inhibit viral reverse transcription; and JNJ-64301736, a therapeutic DNA vaccine delivered via Ichor Medical Systems' TriGrid electroporation technology to induce T-cell responses against HBV antigens. In 2023, Janssen announced the discontinuation of its hepatitis B research and development portfolio, including this combination program.
- Other names
- REEF-D regimen
02
Targets
HBV Pol (Hepatitis B virus polymerase)HBV RNA (Hepatitis B virus RNA)HBV antigens (Hepatitis B virus antigens)HBc (Hepatitis B virus core protein)
Beyond the preview
Go deeper on JNJ-73763989 + JNJ-64300535 + nucleos(t)ide analogs + JNJ-64301736.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JNJ-73763989 + JNJ-64300535 + nucleos(t)ide analogs + JNJ-64301736.